Introduction {#s1}
============

Successful maintenance and expansion of anti-HIV-1 therapy programs in resource-limited settings is determined by multiple factors, such as clinical thresholds to start antiretroviral therapy (ART), drug access, trained personnel, and laboratory infrastructure. World Health Organization (WHO) guidelines for HIV-1 therapy in adults recommend initiation of anti-HIV-1 therapy after CD4 count drops below 350 cells/µl, with a clear indication to treat irrespective of clinical state if the CD4 count is below 200 cells/µl [@pmed.1001207-World1]. While the ideal monitoring of response to ART is dual (virological monitoring with high-sensitivity PCR as the benchmark to assess viral suppression, and monitoring of ART-mediated immune reconstitution via assessment of change in CD4 count [@pmed.1001207-Delta1]--[@pmed.1001207-Badri1]), this level of monitoring is often unsustainable within national health programs in resource-constrained settings because of the cost and limitations of the healthcare system infrastructure [@pmed.1001207-Mangham1]--[@pmed.1001207-Abimiku1]. Although development of viral resistance linked to ineffective monitoring remains a concern in resource-poor settings, monitoring of clinical response (i.e., initial weight gain) and immune reconstitution (i.e., rise in CD4 cell counts) has been broadly used as a primary tool to assess success of therapy: there is a direct relationship between a lack of clinical response or a lack of a rise in CD4 count and risk of developing or not recovering from opportunistic infections. Indeed, WHO guidelines for patient monitoring address the imbalance between increasing treatment access and limited monitoring capacity by promoting therapy success definitions such as frequency of patients with CD4 count \>200 cells/µl at 6, 12, and 24 mo after starting ART [@pmed.1001207-World1].

Despite the advent of newer, more cost-effective point-of-care devices for CD4^+^ T cell count determination using peripheral or capillary blood, the cost of laboratory-based CD4 count determinations to determine disease progression, indication for therapy, and response to ART remains high in terms of both economic and human resources (i.e., the need for specialized instrumentation and trained laboratory staff). Thus, numerous attempts have been made to identify low-cost surrogate markers that are widely available even in resource-limited settings, with the intent of eliminating the need for such intense CD4 count testing within resource/capacity-limited national HIV therapy programs [@pmed.1001207-Chen1]. The WHO recommends the use of total lymphocyte count to monitor untreated chronic HIV infection as a surrogate for disease progression changes, recommending treatment for patients with TLC\<1,200 cells/µl [@pmed.1001207-World1]. While useful in the context of when to start treatment, TLC and other surrogate markers have not been shown to be useful in monitoring therapy response and/or treatment failure [@pmed.1001207-Calmy1]--[@pmed.1001207-Gitura1]. To date, no strategy has been proposed to reduce the need for CD4 testing after ART.

Using prediction-based classification (PBC) [@pmed.1001207-Foulkes1], a recently described model-based approach that accommodates repeatedly measured quantitative biomarkers for outcome prediction, we have developed a prioritization strategy to monitor response to ART based on baseline CD4 count, prospective white blood cell count (WBCC), and lymphocyte percent (Lymph%) measurements. In contrast to previous attempts focused on providing a direct surrogate marker for CD4 count, our approach could be used to direct limited healthcare resources to high-priority patients classified below predetermined CD4 count thresholds of clinical significance.

Methods {#s2}
=======

Cohorts {#s2a}
-------

Anonymized data (WBCC, Lymph%, and CD4 count) were obtained from a cohort of 3,357 HIV-1-infected, ART-naïve individuals at the following clinical sites: Royal Free Hampstead NHS Trust, London, UK (used to generate the prediction rule); University of Alabama at Birmingham, Birmingham, Alabama, US; Jonathan Lax Center, Philadelphia FIGHT, Philadelphia, Pennsylvania, US; University of Malaya, Kuala Lumpur, Malaysia; University of the Witwatersrand, Johannesburg, South Africa; Fundación Huésped, Buenos Aires, Argentina; and University of British Columbia, Vancouver, British Columbia, Canada, for a total of 32,974 cumulative observations. Individual contributions from each site are summarized in [Table 1](#pmed-1001207-t001){ref-type="table"}. Participants were repeatedly observed for up to 3 y after ART initiation, and all patients had at least one post-initiation-of-ART (baseline) assessment. There were no restrictions on initial CD4 count.

10.1371/journal.pmed.1001207.t001

###### Cohort description.

![](pmed.1001207.t001){#pmed-1001207-t001-1}

  Cohort        Site                                                                                     
  ---------- ----------- ------------- ---------- ---------- --------------- ---------- ---------------- ----------------
  Total       100 (542)   270 (2635)    35 (102)   72 (399)   1,351 (4,239)   66 (640)   1,463 (24,336)   3,357 (32,893)
  Cohort 1    58 (217)    214 (1,375)   15 (45)    55 (223)    654 (2,058)    59 (292)    901 (5,985)     1,956 (10,195)
  Cohort 2    15 (147)     49 (679)      0 (0)      5 (43)        0 (0)       32 (398)    518 (8,559)      619 (9,826)

Data are expressed as number of individuals (number of observations over time). Cohort 1 is composed of individuals with complete data---between one and six assessments (CD4^+^ T cell count, WBCC, and Lymph% measured at the same time) within each 6-mo interval---for 1 y of follow-up. Cohort 2 is composed of individuals with complete data for 3 y of follow-up.

Primary analysis is focused on a subset of individuals (*n* = 1,956; Cohort 1) with complete data, defined as having at least one assessment (CD4^+^ T cell count, WBCC, and Lymph% measured at the same time) and no more than six assessments in each 6-mo period of follow-up---for 1 y after initiation of ART. Additionally, we consider a subset of these individuals (*n* = 619; Cohort 2) with complete data for 3 y of follow-up to assess the longer-term feasibility of this strategy.

Statistical Analysis {#s2b}
--------------------

We applied the PBC algorithm, which in brief involved fitting a mixed-effects model to the repeated measures of CD4 counts and, in turn, using model-derived estimates to define a prediction rule for whether post-baseline (start of ART) observations would be above predefined thresholds of 200 and 350 CD4^+^ T cells/µl. Patients with values predicted to be below these thresholds would be prioritized for actual CD4 testing. Algorithm performance compared to an alternative generalized linear modeling approach is detailed in Foulkes et al. [@pmed.1001207-Foulkes1] and includes improvements in sensitivity, positive predictive value, and negative predictive value for the same false positive rate (FPR). Briefly, the primary advantages of PBC over alternative strategies are the following: (1) PBC draws strength from the full range of continuous outcomes (through application of a linear model) while offering clinically relevant measures (such as positive and negative predictive value) through subsequent classification; and (2) it incorporates simultaneously multiple, repeatedly measured biomarkers observed at unevenly spaced intervals.

Formally, the PBC algorithm with cross-validation (CV) is given as follows, with additional details and formal mathematical derivations provided in Foulkes et al. [@pmed.1001207-Foulkes1]. Re-substitution estimates were determined using the same algorithm detailed below, with the full cohort used in place of both the learning and test samples (i.e., removing steps 1 and 7).

PBC Algorithm {#s2c}
-------------

### Step 1 {#s2c1}

We first randomly selected a learning sample composed of approximately 90% of the individuals in the full cohort to derive the prediction rule. Sample data included baseline (defined as time of ART initiation) and repeated measurements of CD4 count, WBBC, and Lymph% up to 3 y after ART initiation. The remaining approximately 10% of individuals made up the test sample.

### Step 2 {#s2c2}

Based on the learning sample selected in step 1, we fitted a mixed-effects change-point model to repeatedly measured CD4 counts, with fixed effects for allowing different slopes before and after 1 mo on ART, and random person-specific intercept and slope terms (for time). The two time slopes are intended to reflect the rapid rise in CD4 count during the first month after ART initiation, and then the more gradual increase in CD4 over the remaining observation time. Additional fixed-effects terms for baseline CD4 count and baseline and time-varying WBCC and Lymph% are included as predictor variables. Also included in the model are fixed interaction effects between baseline CD4 count and (1) time before and after the change point, (2) baseline and time-varying values of WBCC, and (3) baseline and time-varying values of Lymph%. All terms in the model have Wald test statistic *p*-values of less than 0.10 for the complete cohort analysis, and main effects are included when corresponding interaction effects are statistically significant. Notably, application of a less stringent level 0.10 test is appropriate at this stage given that the algorithm additionally includes implementation of a CV procedure. Model fitting is performed using the lme() function of the nlme package in R version 2.11.1.

### Step 3 {#s2c3}

Based on the model-based estimates derived in step 2, we calculated predicted values of CD4 count for all post-baseline observations in the learning sample. We also determined the lower bounds of corresponding one-sided level-α prediction intervals for a range of α values. Details about the calculation of these prediction intervals, including derivation of the prediction variance, as well as a discussion of their interpretation as credible intervals are provided in Foulkes et al. [@pmed.1001207-Foulkes1]. For a given α, the lower bound is denoted for the *j*th time point for individual *i*. A new binary predicted response, denoted for the *j*th time point for individual *i*, is then defined as an indicator for whether the corresponding lower bound is greater than *K* where *K* = 200 or 350. That is, we letfor each CD4 threshold *K* = 200 and 350. We selected 200 CD4^+^ T cells/µl as indicative of a risk of development of opportunistic infections, and 350 CD4^+^ T cells/µl, the WHO-recommended ART initiation threshold [@pmed.1001207-World1], defining high-priority patients (i.e., patients requiring laboratory-based testing) as those failing to maintain CD4 counts above either of these thresholds after ART initiation.

### Step 4 {#s2c4}

Again based on the learning sample, we compared the predicted variable to an indicator for whether the observed CD4 count is greater than *K*, which we denote , whereand CD4*~ij~* is the observed CD4 count at the *j*th time point for individual *i*. To measure a prediction rule for a given α level and *K*, we calculated the FPR, defined as the proportion of post-baseline observations that fall below the threshold but are predicted to be above the threshold among those observed to be below the threshold.

### Step 5 {#s2c5}

The "optimal" prediction rule was defined for a given threshold *K* as the rule (across all rules defined by the range of α values) that maximizes the FPR in the learning sample, subject to the constraint that the FPR is less than a predefined cut point. FPR cut points of 5% and 10% were considered clinically relevant. The α level corresponding to this optimal rule, denoted α^optimal^, was fixed for all subsequent analyses in the test sample.

### Step 6 {#s2c6}

The test sample data were used to evaluate the optimal prediction rule as follows. Baseline CD4 counts, time since ART initiation, and baseline and post-baseline WBCC and Lymph% were used as inputs in the model derived in step 2 above to arrive at predicted CD4 counts at all measured post-baseline time points for individuals in the test sample. Notably, it is assumed that post-baseline CD4 count is not observed in the test sample, and so a correction for the empirical Bayes estimates from the mixed model is required, as described in Foulkes et al. [@pmed.1001207-Foulkes1]. Corresponding lower bounds for one-sided level-α^optimal^ prediction intervals were determined. Formally, this is denoted for the *j*th time point for individual *i* in the test sample. Binary predictions for all post-baseline CD4 counts within the test cohort were then defined according to Equation 1 where was replaced with . The dichotomized observed CD4 counts, as given by Equation 2, were compared to these binary predictions to arrive at the cross-validated estimates of sensitivity, specificity, positive predictive value, negative predictive value, and capacity savings. Capacity savings is defined as the ratio of tests spared by use of the model (i.e., the number across all individuals of post-baseline time points at which CD4 count is predicted to be above the *K* threshold, and thus a CD4 test would not be performed, divided by the total number of post-baseline time points).

Steps 1 to 6 are repeated ten times, and the average and standard deviation (SD) of the estimates listed in step 6 are reported as CV estimates. As these parameters are interdependent, CV estimates are not consistently lower (or higher) than re-substitution estimates using the full cohort. Copies of the R scripts used are available at <http://people.umass.edu/foulkes/software.html>.

Results {#s3}
=======

Cohort Description and Follow-Up {#s3a}
--------------------------------

The geographical distributions of patients and corresponding numbers of observations over time are summarized in [Table 1](#pmed-1001207-t001){ref-type="table"}. For Cohort 1, the median baseline (pre-ART) CD4 count was 145.5 cells/µl; 34% of the patients initiated ART with a CD4 count \>200 cells/µl, and 14.3% with a CD4 count \>350 cells/µl. Median baseline WBCC was 4.7×10^3^ cells/µl, and median Lymph% was 30.7%. A detailed breakdown of these values for each cohort is summarized in [Table 2](#pmed-1001207-t002){ref-type="table"}. Unlike Lymph% and WBCC, median CD4 count and fraction of patients above 200 or 350 CD4^+^ T cells/µl were higher in the longer follow-up subset (200 for Cohort 2, as compared to 139 for Cohort 1), possibly due to the better clinical outcomes of patients that initiate treatment with higher CD4 counts, as well as the longer average follow-up in the London, Birmingham, and Vancouver cohorts. However, the rate of ART responders, defined as patients who had a documented CD4 raise of at least 20% from baseline over the follow-up time, was similar across all cohorts. The overall response to ART initiation was confirmed by the observed rise of median CD4^+^ T cell count over the observation time, as illustrated in 6-mo intervals in [Figure 1](#pmed-1001207-g001){ref-type="fig"} for the two cohorts.

![Distribution of CD4 count.\
The distribution of CD4 count at 6-mo time intervals was assessed for both Cohort 1 (left) and Cohort 2 (right). Means were calculated for patients with multiple CD4 count assessments in the same interval.](pmed.1001207.g001){#pmed-1001207-g001}

10.1371/journal.pmed.1001207.t002

###### Baseline characteristics.

![](pmed.1001207.t002){#pmed-1001207-t002-2}

  Cohort      CD4 Count (Cells/µl)     Lymph%      WBCC (Cells×10^3^/µl)                                          
  ---------- ---------------------- ------------- ----------------------- ------ ------ ------ ------------ ----- ----------
  Total              139.0           49.0, 238.0           31.3            12.7          30.0   21.7, 38.5   4.7   3.6, 6.0
  Cohort 1           145.5           60.0, 250.0           34.0            14.3   93.1   30.7   23.0, 38.9   4.7   3.7, 6.0
  Cohort 2           200.0           80.5, 340.0           48.6            22.9   97.4   31.7   23.3, 40.0   4.6   3.7, 5.8

Percent of patients with one or more post-baseline visits with CD4 count \>1.2×baseline CD4.

IRQ, interquartile range (25^th^ percentile, 75^th^ percentile).

PBC Application {#s3b}
---------------

The results of fitting mixed-effects change-point models (as described in step 2 of the PBC algorithm) to Cohorts 1 and 2 are given [Table 3](#pmed-1001207-t003){ref-type="table"}. The models suggest that the effects of WBCC, Lymph%, and time (before and after 1 mo on ART) are modified by baseline CD4 count (interaction terms are significant at the 0.10 level), and thus all main effects and interaction terms are included in the final model. The model-based estimates (coefficient estimates in [Table 3](#pmed-1001207-t003){ref-type="table"}) are used to derive the optimal prediction rule (as described in steps 3--5 of the PBC algorithm) using maximum FPRs of 5% and 10%. The results of applying the optimal rule to Cohort 1 data are given in [Table 4](#pmed-1001207-t004){ref-type="table"}. Of the 8,239 post-baseline observations, 5,976 (72.5%) had CD4 count \>200 cells/µl, while 2,263 (27.4%) had CD4 count ≤200 cells/µl. Among observations with CD4 count ≤200 cells/µl, the algorithm correctly classified 2,037 (90%; CV estimate = 91.5%, SD = 4.1%); the corresponding FPR was 226/2,263 = 10% (CV estimate = 8.5%). Prioritized CD4 testing would be recommended for all observations with a predicted CD4 count \<200 cells/µl (*n* = 3,729; 45.5%). The potential capacity savings based on this prioritization scheme, where the likelihood of not detecting a low CD4 count (FPR) is \<10%, is 4,490/8,239 = 54.5% (CV estimate = 54.3%, SD = 4.2%). Alternatively, controlling the FPR at 5% would result in the option to prioritize testing for more observations (*n* = 4,705; 57.1%) and would result in a capacity savings of 42.9% (CV estimate = 44.4%, SD = 4.2%).

10.1371/journal.pmed.1001207.t003

###### Mixed-effects change-point modeling results for Cohort 1.
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  Cohort                                 Variable                           Coefficient Estimate   Standard Error   *t*-Value   *p*-Value
  -------------- --------------------------------------------------------- ---------------------- ---------------- ----------- -----------
  **Cohort 1**                          (Intercept)                               −66.212              22.817        −2.902       0.004
                                   Baseline CD4 (BL_CD4)                           1.011               0.101         10.053       0.000
                                     Time (in months)                              37.424              19.331         1.936       0.053
                        \[Time−1\]+[a](#nt104){ref-type="table-fn"}               −28.515              19.419        −1.468       0.142
                                Baseline Lymph% (BL_Lymph%)                        −0.119              0.318         −0.374       0.708
                  Baseline WBCC (BL_WBCC)[b](#nt105){ref-type="table-fn"}          19.247              16.466         1.169       0.243
                                          Lymph%                                   2.012               0.212          9.484       0.000
                           WBCC[b](#nt105){ref-type="table-fn"}                   117.441              12.326         9.528       0.000
                                     BL_CD4\*BL_Lymph%                             −0.008              0.001         −5.662       0.000
                                      BL_CD4\*BL_WBCC                              −0.521              0.066         −7.899       0.000
                                      BL_CD4\*Lymph%                               0.007               0.001          8.635       0.000
                                       BL_CD4\*WBCC                                0.282               0.044          6.357       0.000
                                       BL_CD4\*Time                                0.139               0.079          1.745       0.081
                                    BL_CD4\*\[Time−1\]+                            −0.148              0.080         −1.850       0.064
  **Cohort 2**                          (Intercept)                               −64.254              48.206        −1.333       0.183
                                   Baseline CD4 (BL_CD4)                           0.890               0.221          4.031       0.000
                                     Time (in months)                              63.075              39.389         1.601       0.109
                        \[Time−1\]+[a](#nt104){ref-type="table-fn"}               −56.659              39.409        −1.438       0.151
                                Baseline Lymph% (BL_Lymph%)                        −0.730              0.672         −1.086       0.278
                  Baseline WBCC (BL_WBCC)[b](#nt105){ref-type="table-fn"}         −46.320              47.386        −0.977       0.329
                                          Lymph%                                   2.245               0.253          8.865       0.000
                           WBCC[b](#nt105){ref-type="table-fn"}                   152.095              17.088         8.901       0.000
                                     BL_CD4\*BL_Lymph%                             −0.005              0.002         −2.111       0.035
                                      BL_CD4\*BL_WBCC                              −0.272              0.140         −1.950       0.052
                                      BL_CD4\*Lymph%                               0.003               0.001          3.832       0.000
                                       BL_CD4\*WBCC                                0.233               0.056          4.139       0.000
                                       BL_CD4\*Time                                0.320               0.189          1.691       0.091
                                    BL_CD4\*\[Time−1\]+                            −0.332              0.189         −1.756       0.079

\[Time−1\]+ indicates the positive component of \[Time−1\], given as follow-up time after the first month for Time \>1 mo, and 0 for Time ≤1 mo.

WBCC is scaled by (divided by) a factor of ten.

10.1371/journal.pmed.1001207.t004

###### Observed and predicted values resulting from application of PCB to Cohort 1.
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  Predicted Value                                       Observed CD4 Count \>200 cells/µl   Observed CD4 Count \<200 cells/µl       Total
  ---------------------------------------------------- ----------------------------------- ----------------------------------- ---------------
  Predicted CD4 \>200                                             4,264 (51.7%)                        226 (2.7%)               4,490 (54.5%)
  Predicted CD4\<200[a](#nt107){ref-type="table-fn"}              1,712 (20.8%)                       2,037 (24.7%)             3,749 (45.5%)
  Total                                                           5,976 (72.5%)                       2,263 (27.5%)             8,239 (100%)

Data are expressed as number of observations (percent of total).

Prioritized CD4 testing recommended for this group.

These results, as well as the results from applying a 350-cells/µl threshold for CD4 count, are summarized in [Figure 2](#pmed-1001207-g002){ref-type="fig"} for both cohorts. Additional details on cross-validated parameter estimates, including sensitivity, specificity, negative predictive value, positive predictive value, and capacity savings, as well as corresponding SDs, are provided in [Table 5](#pmed-1001207-t005){ref-type="table"} for both cohorts and thresholds. Extending this analysis to Cohort 2 (inclusive of 3 y of follow-up) resulted in overall similar capacity savings results, indicating that the model is applicable for at least 3 y from ART initiation without any intervening CD4 count assessment.

![Summary of model performance.\
(A) Cross-validated estimates of FPRs. The bars represent the number of observed post-baseline observations below the thresholds indicated on the *x-*axis and at the indicated FPRs for Cohort 1 (left) and Cohort 2 (right). The dark shading indicates the number of observations correctly identified for laboratory-based CD4 testing (i.e., CD4 counts predicted to be and observed to be below threshold); lighter shading represents false positives (CD4 count incorrectly predicted as above threshold); cross-validated estimates of the FPRs are indicated above each bar. (B) Capacity savings (CS) estimates. Dark shading indicates the number of observations in Cohort 1 (left) and Cohort 2 (right) predicted to require laboratory-based CD4 testing (i.e., CD4 count predicted to be below threshold), and light shading the number of observations predicted to not require laboratory testing (i.e., CD4 count predicted to be above threshold) at the CD4 count threshold and FPR indicated below each bar.](pmed.1001207.g002){#pmed-1001207-g002}

10.1371/journal.pmed.1001207.t005

###### Re-substitution and CV counts and estimates for the PBC model.
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  Cohort    *K* [a](#nt108){ref-type="table-fn"}   FPR[b](#nt109){ref-type="table-fn"}   Observed CD4 Count\>*K*   Observed CD4 Count\<*K*   Sensitivity[c](#nt110){ref-type="table-fn"}   Specificity[c](#nt110){ref-type="table-fn"} ^,^ [d](#nt111){ref-type="table-fn"}   PPV[c](#nt110){ref-type="table-fn"}   NPV[c](#nt110){ref-type="table-fn"}   Capacity Savings[c](#nt110){ref-type="table-fn"}                       
  -------- -------------------------------------- ------------------------------------- ------------------------- ------------------------- --------------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------- ------------------------------------- -------------------------------------------------- -------------------- --------------------
  1                         200                                   0.10                            4,264                     1,712                                226                                                            2,037                                                 0.71 (0.73; 0.048)                    0.90 (0.92; 0.041)                           0.95 (0.96; 0.020)                  0.54 (0.57; 0.051)   0.54 (0.54; 0.042)
                                                                  0.05                            3,421                     2,555                                113                                                            2,150                                                 0.57 (0.60; 0.050)                    0.95 (0.95; 0.031)                           0.97 (0.97; 0.018)                  0.46 (0.49; 0.041)   0.43 (0.44; 0.042)
                            350                                   0.10                            2,348                     1,094                                478                                                            4,319                                                 0.68 (0.73; 0.044)                    0.90 (0.89; 0.036)                           0.83 (0.82; 0.048)                  0.80 (0.82; 0.034)   0.34 (0.37; 0.039)
                                                                  0.05                            1,908                     1,534                                239                                                            4,558                                                 0.55 (0.58; 0.064)                    0.95 (0.94; 0.032)                           0.89 (0.88; 0.057)                  0.75 (0.76; 0.043)   0.26 (0.27; 0.039)
  2                         200                                   0.10                            5,234                     2,548                                142                                                            1,283                                                 0.67 (0.71; 0.050)                     0.9 (0.88; 0.087)                           0.97 (0.97; 0.022)                  0.33 (0.35; 0.053)   0.58 (0.62; 0.048)
                                                                  0.05                            3,998                     3,784                                71                                                             1,354                                                 0.51 (0.53; 0.072)                    0.95 (0.95; 0.043)                           0.98 (0.98; 0.015)                  0.26 (0.27; 0.041)   0.44 (0.46; 0.065)
                            350                                   0.10                            2,993                     2,402                                381                                                            3,431                                                 0.55 (0.55; 0.048)                    0.90 (0.90; 0.034)                           0.89 (0.89; 0.026)                  0.59 (0.58; 0.048)   0.37 (0.37; 0.050)
                                                                  0.05                            2,147                     3,248                                188                                                            3,624                                                  0.4 (0.41; 0.046)                    0.95 (0.95; 0.027)                           0.92 (0.92; 0.031)                  0.53 (0.52; 0.049)   0.25 (0.26; 0.041)

K: CD4^+^ T cell count threshold (cells/µl).

FPR, assigned.

Re-substitution estimate (mean CV estimate; SD of cross-validated estimates).

Fixed, as determined by FPR.

NPV, negative predictive value; PPV, positive predictive value.

Application Examples and Test Cost Comparison {#s3c}
---------------------------------------------

To illustrate the potential use of the model to provide individual predictions, we applied our algorithm to six representative individuals, selected from Cohort 2, based on initial CD4 count and the availability of multiple assessments. In the patients tested ([Figure 3](#pmed-1001207-g003){ref-type="fig"}), the model performed well in prediction of a CD4 count \>200 cells/µl (green dots); in fact, it was always correct in these cases, whereas, as expected, at some of the visits, patients predicted to have CD4 count ≤200 cells/µl (red dots) actually had a CD4 count \>200 cells/µl (false negatives). As all cases predicted to be below threshold should be tested using the traditional laboratory-based methods, real time application of the model would not have exposed any of these patients to an undetected dangerous CD4 count, while sparing 20 (57%) of the 35 CD4 laboratory tests performed after baseline.

![PBC predictive model application.\
The PBC predictive model (FPR 10%, CD4 threshold = 200 cells/µl) was applied to six patients form Cohort 2 (cases 1--6), selected to represent a range of baseline CD4^+^ T cell counts (low, case 1 and 2; medium, case 3--5; and high, case 6). The red and green lines represent assessed WBCC (WBC) and Lymph%, respectively; the blue line represents assessed CD4^+^ T cell count. The PBC algorithm application prediction at the corresponding visits is represented by red dots (predicted CD4^+^ T cell count ≤200 cells/µl, requiring laboratory-based testing) or green dots (predicted CD4^+^ T cell count \>200 cells/µl, no laboratory-based testing required).](pmed.1001207.g003){#pmed-1001207-g003}

To assess the feasibility of the application of our modeling scheme to a healthcare setting scenario, we compared cost estimates for the PBC approach (at 200- and 350-cells/µl thresholds) to the estimated costs of a high-cost CD4 testing method (dual platform assessment) and a low-cost alternative (Guava platform, Millipore) as applied to a constrained-resource setting (South Asia). The details of this comparison are reported in [Table S1](#pmed.1001207.s001){ref-type="supplementary-material"}. Briefly, according to our literature-based cost estimations, the PBC approach (considering a single initial laboratory-based CD4 assessment, followed by PBC application with a complete blood count performed for each individual, and CD4 assessment only for individuals predicted to have below-threshold CD4 values) could result in test cost savings when complete blood count cost is below "breakeven points" ranging from US\$10.90 (PBC with 200-cells/µl threshold, CD4 laboratory testing based on dual platform assessment) to US\$1.38 (PBC with 350-cells/µl threshold, Guava-platform-based laboratory CD4 testing). Importantly, the estimated cost of PBC (US\$0.80) is well below all of these thresholds, suggesting that the PBC method may prove to be a cost-effective treatment monitoring strategy in future cost-effectiveness analyses.

Discussion {#s4}
==========

We demonstrate that after obtaining a baseline WBCC and Lymph% and one laboratory-based CD4^+^ T cell assessment, the response to ART can be monitored relying on relatively low-cost clinical laboratory tests (i.e., WBCC and Lymph%) by using the PBC approach. This method enables us to predict whether CD4^+^ T cell count remains above predetermined safety thresholds with an estimated cross-validated FPR of 8.5%, and could potentially lead to testing capacity savings as compared to monitoring approaches based solely on repeated laboratory-based CD4 tests.

Given the high economic and capacity cost of laboratory-based CD4 assessments [@pmed.1001207-Pattanapanyasat1],[@pmed.1001207-Peter1], and the limited number of available accredited laboratories [@pmed.1001207-Peter2],[@pmed.1001207-Marinucci1]---circumstances that tax already stretched health systems as they implement national HIV treatment programs---a number of surrogate assessments (e.g., TLC) have been proposed to assess when HIV-infected patients require treatment, and to monitor them while they are undergoing treatment [@pmed.1001207-Chen1],[@pmed.1001207-Calmy1],[@pmed.1001207-Bagchi1],[@pmed.1001207-Miiro1],[@pmed.1001207-Kumarasamy1],[@pmed.1001207-Mahajan1]. Since to date these surrogates have not performed as well as CD4 counts in monitoring response to ART [@pmed.1001207-Calmy1]--[@pmed.1001207-Gitura1], two other options are open to improve current capacity utilization: (1) reducing the economic and human resource cost of performing laboratory-based CD4 tests, and/or (2) optimizing the use of existing resources to test only patients who are likely to need testing (i.e., patients likely to have dangerously low CD4 counts). The use of approaches that allow triaging patients at highest risk (e.g., patients who are failing treatment) for laboratory-based CD4 testing is expected to be particularly beneficial in resource-constrained settings characterized by high testing volume requirements (e.g., expanding treatment programs in sub-Saharan Africa).

Based on this premise, we conceived an algorithm that is intended as a triage/prioritization tool. To ensure the reasonableness of the approach, we fixed the acceptable FPR at 0.05 or 0.1. Although minimizing the FPR is desirable, there is an inevitable trade-off between the FPR and capacity savings. We believe that this error rate (5%--10%) is acceptable in light of the intrinsic variability of laboratory-based CD4 testing, and therefore clinically relevant.

Notably, erroneously predicting a CD4 count to be below 200 or 350 cells/µl when it is above this level (1−sensitivity) is less relevant to patient safety, as CD4 testing is recommended on predicted failures, thus eliminating the risk associated with this form of misclassification.

Our testing and validation indicate that the proposed model worked well over the 3-y follow-up time in our dataset. The possibility that periodic laboratory-based CD4 testing (e.g., every year) would improve and/or extend the predictive life of the model, to the point that it could be used continuously after ART initiation, remains open, as its determination will require dedicated prospective studies.

Our comparison of CD4 testing cost estimates indicates that the use of the PBC strategy is anticipated to result in a potential capacity and possibly cost savings at all the threshold levels assessed ([Table S1](#pmed.1001207.s001){ref-type="supplementary-material"}). Further prospective healthcare economic studies modeling primary data (inclusive of all monitoring costs) obtained in target countries will be required to perform a net cost comparison, formally assessing the ramifications of the application and limitations of PBC testing for individual countries/regions\' testing capacity, as well as long-term cost per outcome. While such studies are beyond the scope of this article, the data presented here provide a strong rationale for such studies.

Notably, the model-derived estimates and predictive rule are first derived based on application of PBC to a large cohort, as described in this article. Through development of publicly accessible web-based tools that incorporate the results presented herein, the above-described scenarios can be applied to single-case analyses. Additional contributions to this data resource will likely allow for further model refinement and improvements in predictive performance.

Applications {#s4a}
------------

In light of the considerations discussed above, our PBC-based tool could be useful in a number of scenarios.

### Prioritization/triage of CD4^+^ T cell count testing at the laboratory level {#s4a1}

In this case, a laboratory receiving a request for blood differential and CD4 count would first perform the differential, which requires limited time and commonly available resources; using the information obtained from this differential (WBCC and Lymph%), as well as the historic pre-ART baseline CD4 count (either stored or provided by the clinic), the laboratory could then run the prediction algorithm, and proceed to test only those patients who are predicted to have a CD4 count below a predetermined threshold.

### Expansion of ART response monitoring at the clinic level {#s4a2}

Due to cost limitations, some rollout programs allow only limited CD4 testing (e.g., every 6 mo). If ART-treated patients are additionally monitored at the rollout clinics for clinical visits and ART medication refills (e.g., every 3 mo), all patients could be monitored at these "non-CD4" visits for ART response by drawing a blood sample for a blood differential. Once the WBCC and Lymph% results are obtained from the laboratory, the clinic could employ the prediction tool to predict whether or not the patient\'s CD4 count is below a clinically meaningful threshold. Based on this, patients who are predicted to be failing treatment can be counseled for adherence, and/or further monitored by requesting a CD4 count. Because of the anticipated wider availability of complete blood count testing as compared to CD4 testing, this approach may result in shorter result turnaround time, partially reducing the acute need for point-of-care CD4 testing [@pmed.1001207-Zachariah1].

### Reduction of confirmatory CD4 tests {#s4a3}

Due to the intrinsic variability of current CD4 count tests, in many circumstances laboratory-based CD4 tests yield unexpected or doubtful results that are not in keeping with clinical observations (e.g., unexpectedly low CD4 count in a patient with increasing WBCC, lymphocytes, hemoglobin, or weight, and controlled viral load). In such cases, the CD4 count test may need to be repeated for confirmation before any clinically relevant action is taken (e.g., adherence counseling or regimen alteration and resistance testing). The use of the PBC method to independently confirm unexpected laboratory-tested CD4 counts could limit the need for repeated CD4 measures.

As indicated throughout this section, our conclusions should be tempered by considering some of the limitations of this work. First, this work is not intended to provide a complete analysis of the economic and healthcare outcomes of the application of PBC. Future prospective studies based in actual resource-constrained settings will be required to demonstrate the feasibility of this approach; here we focus on providing the foundation and rationale for such studies, which will be required to assess whether or not implementation of a PBC-based monitoring approach is a viable alternative to repeated CD4 testing. Second, it remains to be assessed how long this approach can be extended in time, e.g., by adding periodic CD4 testing, and whether or not periodic viral load testing would improve clinical outcomes of PBC-based monitoring. Third, PBC requires specifying an acceptable FPR. While the assessed rate can be lower, depending on the threshold used, the fact remains that the PBC has an intrinsic, small possibility of error. In light of the wide variability of CD4 count testing results, we do not consider this to be problematic, but it\'s possible that the collection of additional data (and possibly the introduction of other parameters, such as trends over time, into the model) might improve the model fit and improve its accuracy, and should be considered in future study design.

Finally, it is important to remark that the PBC-based method is not intended to substitute for laboratory-based CD4 testing, not to establish a "second tier" of healthcare standard to be applied to developing countries. Rather, we propose that this method is a potentially useful "triage" tool to direct available laboratory testing capacity to high-priority patients. As a tool to optimize the use of existing resources, the implementation of our PBC-based method would be most beneficial in settings where laboratory resources are currently limiting due to funding, human resources, or structural limitations.

Conclusion {#s4b}
----------

We propose a noninvasive, rapid turnaround method that could be applied to predict CD4 failure (i.e., a drop below clinically meaningful thresholds) in HIV-infected patients undergoing ART. By sparing up to 54% of current laboratory-based testing using a CD4 count threshold of 200 cells/µl, the implementation of our method could help focus laboratory-based CD4 count testing capacity on patients with higher likelihood of CD4 failure. This work provides the basis for future prospective testing of the model\'s overall safety, cost-effectiveness, and clinical outcomes in low-resource settings.

Supporting Information {#s6}
======================

###### 

**Comparison of monitoring cost estimates for PBC method versus high- and low-cost CD4 testing.**

(DOC)

###### 

Click here for additional data file.
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ART

:   antiretroviral therapy

CV

:   cross-validation

FPR
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Lymph%
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PBC

:   prediction-based classification

SD

:   standard deviation
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:   total lymphocyte count
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:   white blood cell count: WHO, World Health Organization
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